Patient Education Guide
What Is the Wegovy Pill?
Quick Answer: The Wegovy Pill — approved by the MHRA on 11 June 2026 — is the UK's first licensed daily oral GLP-1 receptor agonist for weight management. It contains the same active ingredient as the Wegovy injection (semaglutide), but instead of a weekly jab, it is taken as a once-daily tablet. This guide explains what the pill is, how it works in the body, who it is designed for, and how it compares to other available treatments.Once dailyOral tablet — no needles
25 mgRecommended maintenance dose
~15%Average weight loss over 64 weeks (OASIS-4)
About the Medicine
1. The Active Ingredient: Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that mimics the action of a natural gut hormone called GLP-1. This hormone is released after eating and plays several important roles: it signals to the brain that the body is full, slows the rate at which the stomach empties, and helps regulate blood sugar levels by stimulating insulin release.
In people living with obesity, these hormonal signals can be blunted or insufficient, making it harder to feel satisfied after eating and easier to gain weight. Semaglutide works by activating GLP-1 receptors throughout the body, effectively restoring and amplifying these signals. The result is reduced appetite, smaller portion sizes, less frequent feelings of hunger, and — over time — meaningful, sustained weight loss.
Semaglutide is not a new medicine. It has been used in its injectable form (Wegovy and Ozempic) since receiving MHRA approval for weight management in 2021 and for type 2 diabetes management respectively. The pill form delivers the same molecule — the key difference is how it reaches the bloodstream.
2. How the Pill Works: The SNAC System
Delivering semaglutide in tablet form presented a significant scientific challenge. As a large protein molecule, semaglutide would ordinarily be broken down by stomach acid before it could be absorbed. The Wegovy Pill overcomes this through a technology called the SNAC system — named after its key ingredient, salcaprozate sodium (SNAC).
SNAC acts as an absorption enhancer. When the tablet is taken on an empty stomach with a small amount of plain water, SNAC raises the pH in the immediate area around the tablet, creating a more alkaline local environment that helps protect semaglutide from stomach acid. It also temporarily increases the permeability of the stomach lining, allowing the semaglutide molecule to pass through via a process called transcellular transport — directly into the bloodstream.
This is why the specific dosing instructions — empty stomach, no more than 120ml of plain water, no food or other liquids for 30 minutes — are so important. Any deviation can reduce the amount of semaglutide absorbed, making the medicine less effective.
1
Tablet swallowed
Taken whole with up to 120ml plain water on an empty stomach
2
SNAC activates
Salcaprozate sodium (SNAC) raises local pH and protects semaglutide from stomach acid
3
Absorption occurs
Semaglutide passes through the stomach wall into the bloodstream via transcellular transport
⚠️ Why the routine matters
The SNAC absorption system is highly sensitive to what else is in your stomach. Taking the tablet with food, with too much water, or with other drinks (including tea or coffee) significantly reduces the amount of semaglutide your body absorbs. Following the Sip & Go routine every day is essential for the medicine to work as intended.
Eligibility
3. Who Is the Wegovy Pill For?
The Wegovy Pill is licensed in the UK for adults who meet specific clinical criteria for weight management treatment. As with the injectable form, it is a prescription-only medicine and must be prescribed following a clinical assessment by a qualified healthcare professional.
The Wegovy Pill is particularly well suited to people who are eligible for GLP-1 treatment but have a strong preference to avoid weekly injections — whether due to needle anxiety, lifestyle reasons, or simply preferring a daily tablet routine. It is not suitable for everyone, and a thorough clinical assessment is essential before starting treatment.
| Eligibility criterion | Detail |
|---|---|
| BMI ≥ 30 kg/m² | Clinically obese — the primary licensed indication |
| BMI ≥ 27 kg/m² with a weight-related condition | For example: type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, or cardiovascular disease |
| Age | Licensed for adults (18 years and over) |
| Not pregnant or breastfeeding | Must use effective contraception during treatment; stop Wegovy at least two months before trying to conceive |
| No history of pancreatitis | Patients with a history of pancreatitis should discuss with their prescriber before starting |
| Not using as a substitute for insulin | Wegovy must not replace insulin therapy in people with diabetes |
ℹ️ Prescription only — always via a registered pharmacy
The Wegovy Pill is a prescription-only medicine (POM) in the UK. It must be prescribed following a proper clinical Consultation, not via an unregulated website or a simple online questionnaire. Happy Pharmacy is GPhC-registered (No. 9012585) and follows all MHRA and GPhC prescribing standards.
Evidence
4. What Results Can I Expect?
The Wegovy Pill has been studied in large-scale clinical trials. The key evidence comes from the OASIS-4 trial, which examined the effects of oral semaglutide in adults with obesity over 64 weeks.
The pill delivers broadly similar results to the standard 2.4mg Wegovy injection, making it a genuinely effective option for weight management. The higher-dose 7.2mg injection and Mounjaro currently show greater average weight loss in trials, but individual responses vary considerably — and for many people, the convenience and needle-free nature of the pill makes it the right choice.
| Trial / Treatment | Average Weight Loss | Key Finding |
|---|---|---|
| OASIS-4 — Wegovy Pill (25 mg) | ~15% over 64 weeks | First pivotal trial of oral semaglutide specifically for weight management |
| STEP 1 — Wegovy Injection (2.4 mg) | ~15% over 68 weeks | Established benchmark for injectable semaglutide |
| STEP UP — Wegovy Injection (7.2 mg) | ~20.7% over 72 weeks | Higher-dose injection; MHRA approved January 2026 |
| SURMOUNT-1 — Mounjaro (15 mg) | ~22.5% over 72 weeks | Dual GLP-1/GIP agonist; highest trial results to date |
✅ Results take time — and that's normal
Most people begin to notice reduced appetite and early weight loss within the first few weeks, but the full treatment effect is typically seen once the maintenance dose of 25mg is reached — usually from Month 4 onwards. Combining the Wegovy Pill with healthier eating habits and regular physical activity will support the best possible results.
Comparing Options
5. How the Wegovy Pill Compares to Other Options
Understanding where the pill sits within the wider landscape of available treatments helps patients and clinicians make the most informed choice.
No single treatment is right for every patient. The best choice depends on individual health history, preferences, how a person responds to medication, and clinical guidance from a qualified prescriber. At Happy Pharmacy, our team will help you understand your options and find the approach that is right for you.
| Wegovy Pill | Wegovy Injection 2.4 mg | Wegovy Injection 7.2 mg | Mounjaro 15 mg | |
|---|---|---|---|---|
| Format | Once-daily tablet | Weekly injection | Weekly injection (single pen) | Weekly injection |
| Active ingredient | Semaglutide | Semaglutide | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP agonist |
| Avg. weight loss | ~15% (64 wks) | ~15% (68 wks) | ~20.7% (72 wks) | ~22.5% (72 wks) |
| MHRA approved | June 2026 | 2021 | January 2026 | 2023 |
| Needle-free | ✓ Yes | ✗ No | ✗ No | ✗ No |
| Timing restrictions | Empty stomach, 30-min wait daily | Any time, with or without food | Any time, with or without food | Any time, with or without food |
| NHS availability | Pending NICE review | Available (specialist services) | Pending NICE review | Available (specialist services) |
| Private prescription | ✓ Yes | ✓ Yes | ✓ Yes | ✓ Yes |
Safety Information
6. Safety and Important Considerations
As with all medicines, the Wegovy Pill can cause side effects. The most common are gastrointestinal — including nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These are very common, affecting more than 1 in 10 people, but they typically improve over time as the body adjusts to the medication.
The dose escalation schedule — starting at 1.5mg and gradually increasing to the 25mg maintenance dose over approximately four months — is specifically designed to minimise these side effects. Starting low and going slow gives the digestive system time to adapt.
⚠️ Seek urgent advice for eyesight changes
If you notice sudden or rapidly worsening changes to your eyesight, seek urgent medical attention. A very rare but serious side effect called non-arteritic anterior ischaemic optic neuropathy (NAION) has been reported in patients taking semaglutide.
Always inform your prescriber of all other medicines you are taking, including levothyroxine (thyroid medication) and warfarin or other blood-thinning medicines, as semaglutide can interact with these.
When Not to Use the Wegovy Pill
- If you are pregnant, breastfeeding, or planning a pregnancy within two months
- If you are allergic to semaglutide, salcaprozate sodium (SNAC), or magnesium stearate
- If you have a history of pancreatitis — discuss with your prescriber
- As a substitute for insulin if you have diabetes
- If you have delayed stomach emptying (gastroparesis) — speak to your doctor first
Common Questions
Frequently Asked Questions
They contain the same active ingredient — semaglutide — but they are different products. The injection delivers semaglutide subcutaneously (under the skin) once a week. The Wegovy Pill delivers semaglutide orally once a day using the SNAC absorption system. The results are broadly similar for the standard doses, though the injectable 7.2mg dose currently shows greater average weight loss.
Switching between formulations is possible and a dedicated guide on this topic is available from Happy Pharmacy. It requires a clinical review and careful timing to ensure continuity of treatment. Always consult your prescriber before making any changes.
Most patients notice a reduction in appetite within the first few weeks. Visible weight loss typically begins in the first month and builds progressively. The full treatment effect is usually seen at the 25mg maintenance dose, reached from Month 4 onwards.
Not yet. The MHRA approved the Wegovy Pill on 11 June 2026, but NHS availability requires a separate assessment by NICE for cost-effectiveness. The pill is currently available via private prescription through GPhC-registered pharmacies such as Happy Pharmacy.
Simply skip the missed dose and take your next tablet the following morning as usual. Do not take two tablets in one day to make up for a missed dose.
Not for at least 30 minutes. The Wegovy Pill must be taken with plain water only, and you should wait a full 30 minutes before eating, drinking anything other than plain water, or taking other oral medicines. This gives the SNAC system time to facilitate absorption.
Start Your Wegovy Pill Journey with Happy Pharmacy
GPhC-registered online pharmacy (No. 9012585) · Safe, clinically assessed access to the Wegovy Pill · Trustpilot Rating: 4.8 ★
Book Your Free Consultation →
1. MHRA. Wegovy (semaglutide) oral tablet — approval summary. GOV.UK, June 2026. | 2. NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875. March 2023. | 3. Novo Nordisk. Wegovy Pill Patient Brochure. UK26SEMO00507. June 2026. | 4. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719. | 5. Efficacy and Safety of Semaglutide 7.2mg in Obesity — STEP UP Trial. American Diabetes Association, 2025. | 6. Electronic Medicines Compendium. Wegovy 1.5mg–25mg film-coated tablets — Summary of Product Characteristics. Novo Nordisk, 2026. | Happy Pharmacy (GPhC No. 9012585). The information in this guide is intended for general educational purposes only and does not replace personalised medical advice.